If your Merchant Center account just went down, the cause probably isn’t in your feed. It’s in your sentences. Most peptide brands that lose access didn’t lose it because of a technical feed error, a missing return policy, or a checkout bug. They lost it because of copy. Your product page is where a reviewer forms an opinion about what you are actually selling, and in this category the wording is almost always what decides the outcome. Google enforces its misrepresentation policy as an egregious violation, so suspension can arrive without a warning, and the trigger is usually a handful of benefit-shaped phrases sitting above a buy button.
The useful part: this is a copy problem, not an engineering problem. You don’t need a developer, a replatform, or a legal budget to fix it. You need a template, a list of banned constructions, and an afternoon. That’s what’s here, the four wording patterns that reliably attract enforcement, a block-by-block anatomy of a compliant page, and three complete templates you can paste and adapt. If you want the wider context first, start with our peptide compliance guide, then come back and do the rewrite.
Why the reviewer reads your product page before your policy page
Classification happens from the page. When a reviewer or an automated system evaluates whether you are selling a laboratory reagent or an unapproved therapeutic, the evidence considered is the page the shopper lands on: the title, the first screen, the description, the images, and the reviews. A terms-of-sale page or a research-use policy buried in the footer is a secondary document. It is read, if at all, after the classification has already been formed.
This matters because of how contradictions are resolved. If your description says a compound supports recovery and your footer says the product is not for human consumption, you have not neutralized the first statement. You have documented that you know the second statement is required and chose to write the first one anyway. Google’s editorial and professional requirements ask that descriptions be accurate and logically connected to the product’s images and specifications. A page that describes physiological outcomes while asserting laboratory-only use fails that connection on its face.
The same logic applies across the healthcare rules. It is worth being precise about what those rules actually say: neither the Merchant Center healthcare and medicines policy nor the unapproved pharmaceuticals and supplements list names research peptides as a category. Both key on how a product is marketed rather than on a roster of molecules. Google Ads states the same principle from the other side: its unapproved substances policy prohibits non-approved products marketed in a way that implies they are safe or effective for a condition, and products that imply equivalency to prescription drugs. Marketing language is the operative fact, which is precisely why the product page carries so much weight. Our peptide policy map lays out which policy surface applies to which asset; this article deals only with the page itself.
The four wording patterns that trigger enforcement
Nearly every flagged peptide page we review contains at least one of four constructions. Learn to recognize them by shape, not by keyword, because keyword lists go stale and the shapes do not.
1. Outcome and benefit language
Any sentence whose subject is a result rather than a substance. These are the easiest to spot and the most consequential, because they place the product in the supplement or therapeutic category regardless of the disclaimer.
- Before: “Supports lean tissue development and shortens recovery windows.”
- Before: “Users report noticeable improvements within four weeks.”
- After: “[COMPOUND NAME], [PURITY] by HPLC, supplied as a lyophilized powder in a [QUANTITY] vial for in vitro laboratory research.”
Notice that the compliant version is not a softened benefit claim. It is a different category of sentence entirely. Hedging (“may support,” “has been associated with”) does not move a page out of the benefit frame; it just makes the claim quieter. The replacement for a benefit sentence is a specification sentence.
2. Implied claims through mechanism-of-action description
The most common trap for technically minded founders. Describing what a molecule does inside a body is a claim, even when written in clinical register and even when every word is accurate.
- Before: “Acts on the [RECEPTOR] pathway to increase endogenous [HORMONE] secretion.”
- After: “[COMPOUND NAME] is a synthetic [PEPTIDE CLASS] of [N] amino acids. Sequence: [SEQUENCE]. Molecular formula: [FORMULA]. Molecular weight: [MW]. CAS: [CAS NUMBER].”
Citations do not launder mechanism copy. A block of PubMed links positioned directly under an add-to-cart button is read in context, and the context is commercial. In our experience this is an observed enforcement pattern rather than a documented rule: the policies do not say “no citations,” but pages that pair literature summaries with purchase intent are classified as marketing the effect. If you want a literature section, keep it off the transactional page and behind a clearly separate research resource area.
3. Prescription-drug comparison and adjacency
Google Ads explicitly prohibits products that imply they are as effective as prescription drugs or controlled substances, and the Merchant Center healthcare policy extends to items with names confusingly similar to banned substances. Adjacency counts even without a direct comparison.
- Before: “A research-grade alternative to [BRAND-NAME DRUG].”
- Before: “Same active pathway as [PRESCRIPTION PRODUCT], without a prescription.”
- After: Delete. There is no compliant rewrite of a comparison to a prescription product on a commerce page. Remove the comparison, the drug name, the branded-drug meta description, and the URL slug that contains it.
This extends to your internal search terms, collection names, and alt text. A collection titled after a drug class does the same classification work as body copy. If your account is already flagged, the sequence for unwinding this is covered in our walkthrough on the misrepresentation fix.
4. User-directed framing
The subtlest pattern and the one founders resist cutting, because it feels like customer service. Any copy addressed to a person who will use the product implies a person will use the product.
- Before: “Reconstitute with 2 mL bacteriostatic water and administer 250 mcg daily for eight weeks.”
- Before: “Your first cycle should start low. Here is how to build your protocol.”
- After: “Solubility: soluble in [SOLVENT] to [CONCENTRATION]. Store reconstituted solution at [TEMPERATURE] for up to [DURATION]. Handling by qualified laboratory personnel only.”
The distinction that keeps you safe is property versus protocol. Solubility, stability, and storage temperature are physical properties of a material and belong in a specification table. Dosing, cycling, scheduling, administration route, and second-person instruction are protocols for a user, and they do not belong anywhere on a research-use page. Strip second person from the product template entirely: no “you,” no “your results,” no “your goals.”
Anatomy of a compliant peptide product page
Work through the page in the order the shopper and the reviewer encounter it. The table below is the fastest audit you can run on an existing page; the sections after it expand the three blocks people get wrong most often.
| Block | What belongs | What must not appear |
|---|---|---|
| Title | Compound name, purity, quantity or fill weight, form, research-use qualifier | Benefit words, drug names, price, sale language, all caps |
| Above-the-fold specification block | Purity, quantity, CAS, form, lot availability, price, stock status | Outcome bullets, testimonials, “best for” framing |
| Description | What the material is, how it is produced, what it is supplied as, who it is sold to | Mechanism, effects, comparisons, user instructions, second person |
| Technical specification table | Sequence, formula, molecular weight, purity method, appearance, solubility, storage | Dosing, administration, cycle length, “typical use” |
| Documentation and COA | Lot-linked COA, test method, testing laboratory, date | Purity claims unsupported by the linked document |
| Storage and handling | Temperature, light and moisture conditions, shelf life, handling precautions | Reconstitution protocols framed as instructions to a person |
| Intended-use statement | One consistent research-use sentence, in the body copy, in normal type | A shouted footer banner with no supporting page context |
| Shipping and returns | Handling time, carrier, cold-chain method, return and refund terms | Discreet-packaging language that implies concealment |
| Structured data | Product, Offer, price, priceCurrency, availability, sku, brand, additionalProperty | Markup that contradicts visible text or feed values |
| Images and alt text | Vial, label, packaging, COA excerpt; alt text describing the object | Bodies, syringes, needles, before-and-after imagery, benefit alt text |
| Reviews | Moderated comments on packaging, purity, shipping, documentation | Any published review describing personal use or effects |
The above-the-fold specification block
Whatever sits in the first screen carries disproportionate weight, because it is what a fast review sees. Replace the marketing hero with five specification lines: purity and method, quantity and form, CAS number, lot and COA link, and the research-use qualifier. This single change resolves a large share of the pages we audit. Run the rest of the page against our research peptide compliance checklist once the hero is fixed.
Documentation and COA block
Documentation is the substitute for persuasion. A page that cannot claim outcomes still has plenty to say: analytical method, purity result, testing laboratory, lot number, and test date. Link the certificate for the specific lot being sold rather than a generic sample document, and make sure the number printed on the certificate matches the number in the specification table. Our guide to COAs and third-party testing covers what a defensible certificate contains and the common gaps reviewers notice. Where the certificate and the page disagree on purity, the page is the problem, and mismatch of that kind reads as a misrepresentation issue rather than a clerical one.
The intended-use statement
One sentence, written in the same voice and type size as the rest of the body copy, placed inside the description rather than appended to the footer. It should state what the material is sold for and who it is sold to. It should not be the only research-use signal on the page, which is the failure mode covered later in this article.
Templates you can paste and adapt
Each template uses placeholder tokens in square brackets. Replace the tokens, delete nothing structural, and resist the urge to add a paragraph of context at the top. The absence of that paragraph is the point.
Template 1: single-compound page
Title: [COMPOUND NAME] [QUANTITY] Vial, [PURITY] — Research Use Only
Above the fold: Purity: [PURITY] by [METHOD]. Quantity: [QUANTITY] per vial. Form: lyophilized powder. CAS: [CAS NUMBER]. Lot: [LOT NUMBER]. COA: linked below. Availability: [IN STOCK / OUT OF STOCK].
Description: [COMPOUND NAME] is a synthetic [PEPTIDE CLASS] supplied as a lyophilized powder in a sealed [QUANTITY] vial. Each lot is manufactured under [PROCESS DESCRIPTION] and analyzed by [METHOD] with results reported on a lot-specific certificate of analysis. [BRAND] supplies this material exclusively to laboratories, research institutions, and qualified professionals for in vitro investigational work. This product is not a drug, food, cosmetic, or supplement, and is not supplied for human or veterinary use.
Specifications: Sequence: [SEQUENCE]. Molecular formula: [FORMULA]. Molecular weight: [MW]. Appearance: [APPEARANCE]. Purity: [PURITY] by [METHOD]. Solubility: soluble in [SOLVENT] to [CONCENTRATION]. Storage: [TEMPERATURE], protected from light and moisture. Shelf life: [DURATION] from date of manufacture in original sealed packaging.
Documentation: Certificate of analysis for lot [LOT NUMBER], issued [DATE] by [TESTING LABORATORY], available at [LINK]. Certificates for prior lots are available on request.
Handling: To be handled by qualified laboratory personnel in an appropriate facility, in accordance with applicable institutional and jurisdictional requirements.
Shipping and returns: Orders ship within [HANDLING TIME] via [CARRIER] with [PACKAGING METHOD]. Unopened vials may be returned within [WINDOW] under the conditions set out in our return policy. Opened vials cannot be returned.
Template 2: blend or multi-item page
Blends attract more scrutiny than single compounds, because a combination invites the question of what the combination is for. Answer it in inventory terms, never in purpose terms.
Title: [BLEND REFERENCE NAME] — [COMPOUND A] [QUANTITY A] and [COMPOUND B] [QUANTITY B], [PURITY] — Research Use Only
Above the fold: Contents: [COMPOUND A] [QUANTITY A]; [COMPOUND B] [QUANTITY B]. Form: [SINGLE VIAL / SEPARATE VIALS]. Purity: [PURITY A] and [PURITY B] by [METHOD]. Lots: [LOT NUMBER A], [LOT NUMBER B]. COAs: linked per component.
Description: This listing supplies [COMPOUND A] and [COMPOUND B] together as a single catalog item for laboratories that source both materials. Each component is manufactured and tested independently, and each carries its own lot number and certificate of analysis. The components are supplied [IN SEPARATE SEALED VIALS / AS A CO-LYOPHILIZED PREPARATION AT A RATIO OF [RATIO]]. No conclusions about combined activity are offered or implied. Supplied for in vitro laboratory research only; not for human or veterinary use.
Component specifications: For each component, list separately: sequence, molecular formula, molecular weight, purity and method, appearance, solubility, storage, shelf life.
Documentation: Certificate of analysis for lot [LOT NUMBER A] and lot [LOT NUMBER B], issued [DATE] by [TESTING LABORATORY].
Do not explain why the two materials are packaged together, do not name the pairing after an outcome, and do not use “stack,” “protocol,” or “cycle” anywhere in the listing. If the blend has an internal reference name that reads as a benefit, rename it before publishing.
Template 3: bundle or kit page
Kits are commonly flagged because ancillary items imply administration. Everything in a kit should be defensible as laboratory equipment, and the description should treat the kit as a packing list.
Title: [KIT REFERENCE NAME] — [N] x [COMPOUND NAME] [QUANTITY], [PURITY] — Research Use Only
Above the fold: Included: [N] x [COMPOUND NAME] [QUANTITY] vial; [N] x [ANCILLARY ITEM]. Purity: [PURITY] by [METHOD]. Lots: [LOT NUMBERS]. COAs: linked per vial.
Description: This kit supplies [N] sealed vials of [COMPOUND NAME] at [QUANTITY] per vial, together with [ANCILLARY ITEM DESCRIPTION] for laboratory storage and handling. Vials are drawn from lot [LOT NUMBER] and each is covered by the certificate of analysis linked below. The kit is a packaging and pricing convenience for laboratories ordering in volume; it does not represent a program, regimen, or sequence of any kind. Supplied for in vitro laboratory research only; not for human or veterinary use.
Contents table: item, quantity, specification, lot, certificate link.
Excluded from kits: syringes, needles, alcohol swabs, injection guides, calendars, tracking sheets, “getting started” inserts, and any item whose only plausible purpose is administration to a person. Bundle pricing language should describe volume, not commitment: “[N] vials at [PRICE]” rather than “[N]-week supply.”
Titles and feed attributes: what has to match
A compliant page that disagrees with your feed produces item disapprovals, and repeated disagreement escalates. Google’s title attribute guidance requires the title to describe the product on the landing page, prohibits promotional text such as price, sale dates, shipping information, and company names, and prohibits all capitals for emphasis. Titles do not need to be character-identical to the page, but they must refer to the same product.
- Title: compound name, quantity, purity, and research-use qualifier. Keep the on-page H1 and the feed title in the same order with the same values. Do not put a benefit word in the feed title that does not appear on the page, and do not put one in either.
- Price: feed price, visible page price, and structured data price must agree, including currency and any taxes or fees disclosed at checkout. Google’s automatic item updates will reconcile some mismatches from your markup, and where extractors cannot determine the value, items are subject to item-level disapproval.
- Availability: the guidance to keep an account approved is explicit that you may only promote products you actually have in stock. Backorder pages presented as in stock are an availability problem that can be read under misrepresentation as an unavailable offer.
- Product category: pick the category that matches what the page describes. Miscategorizing a reagent as a general merchandise item to dodge healthcare review does not work and adds an accuracy problem to whatever else is wrong.
- Structured data: markup is evidence, not decoration. If your Product markup carries a description containing benefit language you deleted from the visible page, the deleted copy is still on the page as far as a crawler is concerned.
For the account-level setup that surrounds these attributes, see our overview of Merchant Center for research peptides, and if you are already dealing with a health-products enforcement action, our guide to health products suspensions covers the appeal sequence.
Structured data specifics
Use Product with name, description, sku, brand, image, and an Offer carrying price, priceCurrency, and availability from ItemAvailability. Put purity, CAS, molecular weight, and storage into additionalProperty as name and value pairs rather than stuffing them into the description string. Two rules: every marked-up value must appear in the visible page, and no marked-up value may say something the visible page does not.
The disclaimer that works versus the disclaimer everyone copies
Almost every peptide site runs some version of the same block: a bolded line stating the products are not for human consumption, sold for laboratory research only, and not evaluated by any regulatory authority. It is copied between sites verbatim, and it fails for three separate reasons.
It is bolted onto consumer-facing copy. The disclaimer does not modify the sentences above it. When the description promises outcomes in second person and the footer denies human use, a reviewer sees a contradiction, and the contradiction resolves toward the commercial framing because that is what the page is built to sell.
It is the only research-use signal on the page. A genuine research catalog looks different from a consumer store in a dozen ways: lot numbers, certificates, specification tables, institutional ordering terms, handling language. When the disclaimer is carrying that load alone, it stands out as compensation rather than description.
It creates a separate problem in payment underwriting. This is an observed pattern rather than a published rule, and it is worth knowing before you make the banner bigger. Acquirers and payment processors reviewing a merchant application treat a prominent “not for human consumption” line as a category signal, not a protection, because it appears most often on sites in high-risk verticals. Founders sometimes make the disclaimer louder after a Google problem and then find that the louder version complicates the payments conversation.
The fix is not a stronger disclaimer. It is consistency, so that the intended-use sentence is the least surprising thing on the page. Delete the benefit copy, build the specification blocks, publish the certificates, moderate the reviews, and then a single plain sentence in the description does real work. Apply the same rules everywhere the copy travels, including the same copy rules applied to email flows, since a post-purchase sequence promising outcomes undoes an otherwise clean page.
Three before-and-after rewrites
These examples are invented composites of patterns we see repeatedly. They are not drawn from any specific brand.
Rewrite 1: the hero paragraph
Before: “Our most popular research peptide. [COMPOUND NAME] works by signaling the body to accelerate tissue repair, and researchers consistently report faster recovery and improved sleep quality. Third-party tested at 99% purity. Not for human consumption.”
After: “[COMPOUND NAME], [PURITY] by HPLC, supplied as a lyophilized powder in a [QUANTITY] sealed vial. Lot [LOT NUMBER], certificate of analysis issued [DATE] by [TESTING LABORATORY]. Sold to laboratories and qualified professionals for in vitro research; not for human or veterinary use.”
What changed: the mechanism clause and the outcome report are gone, “most popular” is gone because popularity is a proxy for efficacy in this category, and the purity claim is now tied to a specific lot and document.
Rewrite 2: the blend listing
Before: “This synergistic blend pairs [COMPOUND A] and [COMPOUND B] for a complete recovery stack. Ideal for advanced research protocols where a single compound is not enough.”
After: “This listing supplies [COMPOUND A] [QUANTITY A] and [COMPOUND B] [QUANTITY B] as a single catalog item. Each component is tested independently and carries its own lot number and certificate of analysis. Combined activity is not characterized and no combined use is proposed.”
What changed: “synergistic,” “stack,” “recovery,” “protocols,” and “advanced” all encode purpose. The replacement describes a packing arrangement and explicitly declines to describe a combined effect.
Rewrite 3: the kit page
Before: “Everything you need to get started. Includes four vials of [COMPOUND NAME], bacteriostatic water, syringes, and our step-by-step starter guide with recommended dosing for beginners.”
After: “Includes four sealed vials of [COMPOUND NAME] at [QUANTITY] per vial from lot [LOT NUMBER], and [N] x [LABORATORY ANCILLARY ITEM] for storage and handling. Certificates of analysis linked per lot. Supplied for in vitro laboratory research only.”
What changed: second-person address, administration hardware, the beginner framing, and the dosing guide are removed. What remains is an inventory list a laboratory purchasing officer would recognize.
Frequently Asked Questions
Can I keep benefit language if it only appears in customer reviews?
No. Reviews sit on the page, so they get read as part of the page. When a reviewer describes personal dosing and results, that’s exactly the evidence that classifies your listing as a consumer health product, and it lands more credibly than anything you would write yourself. So moderate submissions before they publish. Decline any review that describes personal use or physiological effects, and publish the ones that talk about packaging, purity, documentation, and shipping. There’s a second benefit here: it leaves you a consistent record. If you ever need to show that your storefront was governed rather than simply cleaned up after a suspension, that record is what does it.
Do I have to remove scientific citations from product pages?
No policy prohibits citations. The problem is where you put them. A literature summary sitting next to an add-to-cart button gets read as marketing the effect it describes, and that’s an observed enforcement pattern rather than a written rule. The safer structure is to keep transactional pages purely descriptive and move any literature discussion into a clearly separate research resources area: one that doesn’t sell anything, doesn’t link directly to a cart, and doesn’t summarize findings in outcome language. If you’d rather keep the citations on the product page, go in expecting them to be evaluated as claims.
Does adding “research use only” to my feed titles help or hurt?
It helps, as long as the page behind it backs it up. The title attribute guidance prohibits promotional text and gimmicky formatting, and a research-use qualifier is neither. It’s a plain description of what is being supplied. What hurts is a qualifier that contradicts the rest of the listing, such as a research-use suffix on a title that also contains a benefit word or a drug reference. In that case the qualifier isn’t your problem; the rest of the title is. Keep the same qualifier in the feed title, the page H1, and the structured data name so all three agree.
Will rewriting product pages get a suspended account reinstated?
It’s necessary, but it isn’t always sufficient. Misrepresentation is enforced at the account level, so reinstatement depends on a reviewer accepting that the underlying issue is resolved sitewide, not that one page got tidied. Before you appeal, fix every product page, collection page, blog post, and email that carries the same language. A reviewer who finds one surviving benefit claim will treat the whole remediation as incomplete. And when you do appeal, show your work. Appeals with documentation of the changes fare better than appeals that assert compliance. One more thing worth knowing in advance: repeat violations are treated more severely than a first finding.
Should product pages include reconstitution instructions?
Include solubility as a physical property. Don’t include reconstitution as an instruction. The line “Soluble in [SOLVENT] to [CONCENTRATION]” is specification data of the kind any reagent supplier publishes. “Add 2 mL and draw up 250 mcg” is a protocol addressed to a person, and it undermines every research-use statement on the page. The two lines look similar on screen. They aren’t. When customers ask, and they will, handle it through documented technical specifications rather than a how-to block, and never with second-person phrasing or volumes framed as servings.
Will removing benefit copy hurt my organic rankings?
You’ll lose rankings for benefit queries, which are the queries most likely to attract enforcement anyway. Specification-led pages tend to rank well for compound name, purity, CAS number, and quantity queries, and those convert better in a research buyer segment. Build depth through documentation, specification tables, lot histories, and storage data rather than through prose. In our experience the traffic mix shifts toward lower volume with higher intent, and the pages become stable rather than intermittently disapproved.
What do I do about older blog posts that contradict my new pages?
Treat them as part of the same audit. A blog post recommending dosing schedules, or a comparison article naming prescription products, sits on the same domain a reviewer is evaluating, and it can carry more explicit claim language than any product page you own. Unpublish it, rewrite it, or gate it. Anything that addresses a reader as a user has to go. While you’re in there, check your category pages, site search results, internal link anchors, image alt attributes, and meta descriptions too. Those get missed constantly, and they’re all crawlable text.
Nothing here is legal advice, and policy interpretation can change; check the current policy text and consult qualified counsel for your specific situation. If you want the paid side handled alongside the rewrite, read our guide to running compliant Google Ads for peptide brands, or book a free 15-minute consultation and we will look at one of your product pages and tell you what a reviewer would see.
Sources
Every policy and regulatory claim in this article is drawn from the primary documents below, checked on 15 August 2026. Platform policies change without notice; verify against the current version before acting.
- misrepresentation policy — Google
- editorial and professional requirements — Google
- healthcare and medicines policy — Google
- unapproved pharmaceuticals and supplements — Google
- unapproved substances policy — Google
- title attribute guidance — Google
- automatic item updates — Google
- keep an account approved — Google
- Product — Schema.org
- Offer — Schema.org
- ItemAvailability — Schema.org